Treatment of hypertension in patients with diabetes-an update

Journal of the American Society of Hypertension

Volumn 4, Issue 2, 2010, Pages 62-67

  Bakris, George L ^a   Sowers, James R ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b University of Missouri   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUMETANIDE; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CHLORTALIDONE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FUROSEMIDE; GLICLAZIDE; GLUCOSE; HEMOGLOBIN A1C; HYDROCHLOROTHIAZIDE; INDAPAMIDE; INDAPAMIDE PLUS PERINDOPRIL; NEBIVOLOL; RAMIPRIL; RENIN INHIBITOR; SODIUM CHLORIDE; SPIRONOLACTONE; TELMISARTAN; THIAZIDE DIURETIC AGENT; TORASEMIDE; VERAPAMIL;

ALCOHOL WITHDRAWAL; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG TOLERABILITY; EXERCISE; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; HYPOKALEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PRIORITY JOURNAL; SMOKING CESSATION; SODIUM RESTRICTION; SYSTOLIC BLOOD PRESSURE; WEIGHT REDUCTION;

EID: 77952105361     PISSN: 19331711     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jash.2010.03.005     Document Type: Article

References (50)

1. KDOQI. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 49 (2007) S12-S54
2. Stamler J., Stamler R., and Neaton J.D. Blood pressure, systolic and diastolic, and cardiovascular risks. U.S. population data. Arch Intern Med 153 (1993) 598-615
3. Hajjar I., and Kotchen T.A. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 290 (2003) 199-206
4. Kearney P.M., Whelton M., Reynolds K., Muntner P., Whelton P.K., and He J. Global burden of hypertension: analysis of worldwide data. Lancet 365 (2005) 217-223
5. Buse J.B., Ginsberg H.N., Bakris G.L., Clark N.G., Costa F., Eckel R., et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 115 (2007) 114-126
6. Nag S., Bilous R., Kelly W., Jones S., Roper N., and Connolly V. All-cause and cardiovascular mortality in diabetic subjects increases significantly with reduced estimated glomerular filtration rate (eGFR): 10 years' data from the South Tees Diabetes Mortality Study. Diabet Med 24 (2007) 10-17
7. Bakris G.L. The importance of blood pressure control in the patient with diabetes. Am J Med 116 (2004) 30S-38S
8. Sarafidis P.A., and Bakris G.L. State of hypertension management in the united states: confluence of risk factors and the prevalence of resistant hypertension. J Clin Hypertens (Greenwich) 10 (2008) 130-139
9. Whelton P.K., Barzilay J., Cushman W.C., Davis B.R., Iiamathi E., Kostis J.B., et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 165 (2005) 1401-1409
10. Kostis J.B., Wilson A.C., Freudenberger R.S., Cosgrove N.M., Pressel S.L., Davis B.R., et al. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol 95 (2005) 29-35
11. Sarafidis P.A., and Bakris G.L. Antihypertensive therapy and the risk of new-onset diabetes. Diabetes Care 29 (2006) 1167-1169
12. Elliott W.J., and Meyer P.M. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 369 (2007) 201-207
13. Mancia G., Grassi G., and Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens 24 (2006) 3-10
14. Carter B.L., Einhorn P.T., Brands M., He J., Cutler J.A., Whelton P.K., et al. Thiazide-induced dysglycemia: call for research from a working group from the National Heart, Lung, and Blood Institute. Hypertension 52 (2008) 30-36
15. Sarafidis P.A., McFarlane S.I., and Bakris G.L. Antihypertensive agents, insulin sensitivity and new-onset diabetes. Curr Diab Rep 7 (2007) 191-199
16. Sarafidis P.A., and Bakris G.L. Antihypertensive treatment with beta-blockers and the spectrum of glycemic control. QJM 99 (2006) 431-436
17. Bakris G.L., Fonseca V., Katholi R.E., McGill J.B., Messerli F.H., Phillips R.A., et al. Metabolic effects of carvedilol vs. metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 292 (2004) 2227-2236
18. Kaiser T., Heise T., Nosek L., Eckers U., and Sawicki P.T. Influence of nebivolol and enalapril on metabolic parameters and arterial stiffness in hypertensive type 2 diabetic patients. J Hypertens 24 (2006) 1397-1403
19. Bosch J., Yusuf S., Gerstein H.C., Pogue J., Sheridan P., Dagenais G., et al. Effect of ramipril on the incidence of diabetes. N Engl J Med 355 (2006) 1551-1562
20. Bakris G., Molitch M., Hewkin A., Kipnes M., Sarafidis P., Fakouhi K., et al. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 29 (2006) 2592-2597
21. Turnbull F., Neal B., Ninomiya T., Algert C., Arima H., Barzi F., et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 336 (2008) 1121-1123
22. So W.Y., Kong A.P., Ma R.C., Ozaki R., Szeto C.C., Chan N.N., et al. Glomerular filtration rate, cardiorenal endpoints, and all-cause mortality in type 2 diabetic patients. Diabetes Care 29 (2006) 2046-2052
23. Ibsen H., Wachtell K., Olsen M.H., Borch-Johnsen K., Lindholm L.H., Mogensen C.E., et al. Does albuminuria predict cardiovascular outcome on treatment with losartan vs. atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. J Hypertens 22 (2004) 1805-1811
24. Berl T., Hunsicker L.G., Lewis J.B., Pfeffer M.A., Porush J.G., Rouleau J.L., et al. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol 16 (2005) 2170-2179
25. De Zeeuw D., Remuzzi G., Parving H.H., Keane W.F., Zhang Z., Shahinfar S., et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 110 (2004) 921-927
26. Sarafidis P.A., Khosla N., and Bakris G.L. Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis 49 (2007) 12-26
27. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42 (2003) 1206-1252
28. Mancia G., de Backer G., Dominiczak A., Cifkova R., Fagard R., Germano G., et al. 2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 25 (2007) 1105-1187
29. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 43 (2004) S1-S290
30. Saydah S.H., Fradkin J., and Cowie C.C. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 291 (2004) 335-342
31. Wong N.D., Lopez V.A., L'Italien G., Chen R., Kline S.E., and Franklin S.S. Inadequate control of hypertension in U.S. adults with cardiovascular disease comorbidities in 2003-2004. Arch Intern Med 167 (2007) 2431-2436
32. Chua D.C., and Bakris G.L. Is proteinuria a plausible target of therapy?. Curr Hypertens Rep 6 (2004) 177-181
33. Pitt B., Bakris G.L., Ruilope L., et al. EPHESUS investigators. Serum potassium and clinical outcomes in the eplerenone post-acute myocardial infarction heart failure efficacy and survival study. Circulation 118 (2008) 1643-1650
34. Gerstein H.C., Miller M.E., Byington R.P., Goff Jr. D.C., Bigger J.T., Buse J.B., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358 (2008) 2545-2559
35. Patel A., MacMahon S., Chalmers J., Neal B., Billot L., Woodward M., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358 (2008) 2560-2572
36. Lewis E.J., Hunsicker L.G., Clarke W.R., Berl T., Pohl M.A., Lewis J.B., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 (2001) 851-860
37. Gerbino P.P., and Shoheiber O. Adherence patterns among patients treated with fixed-dose combination vs. separate antihypertensive agents. Am J Health Syst Pharm 64 (2007) 1279-1283
38. Bangalore S., Kamalakkannan G., Parkar S., and Messerli F.H. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 120 (2007) 713-719
39. Yusuf S., Teo K.K., Pogue J., Dyal L., Copland I., Schumacher H., et al. Telmisartan, ramipril, or both in patients at high-risk for vascular events. N Engl J Med 358 (2008) 1547-1559
40. Kunz R., Friedrich C., Wolbers M., and Mann J.F. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 148 (2008) 30-48
41. Hart P.D., and Bakris G.L. Should beta-blockers be used to control hypertension in people with chronic kidney disease?. Semin Nephrol 27 (2007) 555-564
42. Bakris G.L., Williams M., Dworkin L., Elliot W.J., Epstein M., Toto R., et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 36 (2000) 646-661
43. Saseen J.J., Carter B.L., Brown T.E., Elliot W.J., and Black H.R. Comparison of nifedipine alone and with diltiazem or verapamil in hypertension. Hypertension 28 (1996) 109-114
44. Pratt-Ubunama M.N., Nishizaka M.K., Boedefeld R.L., Cofield S.S., Harding S.M., and Calhoun D.A. Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest 131 (2007) 453-459
45. Calhoun D.A., Jones D., Textor S., Goff D.C., Murphy T.P., Toto R.D., et al. American Heart Association Professional Education Committee. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 117 (2008) e510-e526
46. Nishizaka M.K., Zaman M.A., and Calhoun D.A. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 16 (2003) 925-930
47. Chapman N., Dobson J., Wilson S., Dahlöf B., Sever P.S., Wedel H., et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 49 (2007) 839-845
48. Krug A.W., and Ehrhart-Bornstein M. Aldosterone and metabolic syndrome: is increased aldosterone in metabolic syndrome patients an additional risk factor?. Hypertension 51 (2008) 1252-1258
49. Smith Jr. S.C., Allen J., Blair S.N., Bonow R.O., Brass L.M., Fonarow G.C., et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 113 (2006) 2363-2372
50. Ruilope L., Kjeldsen S.E., de la Sierra A., Mancia G., Ruggenenti P., Stergiou G.S., et al. The kidney and cardiovascular risk-implications for management: a consensus statement from the European Society of Hypertension. Blood Press 16 (2007) 72-79